magnifying glass
logo for Shanghai Junshi Biosciences

Shanghai Junshi Biosciences

Manufacturing · China · 616 Employees

Get Full Access

Who is Shanghai Junshi Biosciences

Junshi has already produced a robust pipeline of monoclonal antibody drugs which have covered the tumor, cardiovascular disease, osteoporosis, and other fields.About us | Development | Business | Recruiting | Contact usRead More

Headquarters

Headquarters:

No 781, Cailun Rd, Zhangjiang, Shanghai, Shanghai, China
Phone Number

Phone Number:

+86 21 5079 6193
Revenue

Revenue:

$400 Million
Stock Symbol

Stock Symbol:

1877
SIC Code 28,283
NAICS Code 32541,325
Ticker HKEX: 1877
Popular Searches:

Shanghai Junshi Biosciences Co. LTD

Shanghai Junshi Biosciences Co., LTD

Shanghai Junshi Biosciences

Shanghai Junshi Bioscience Co. , LTD

Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences's Org Chart

Linlin Yu
Linlin Yu

Chief Executive Officer

PhonePhoneEmailEmail
Patricia Keegan
Patricia Keegan

Chief Medical Officer

PhonePhoneEmailEmail

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Shanghai Junshi Biosciences Company Metrics

Company Insights
Employee Growth Rate
Revenue
QuarterRevenue

'21 - Q1

122481000

'21 - Q2

122481000

Shanghai Junshi Biosciences's Tech Stack

Jira

By

Atlassian

Microsoft Dynamics 365 Business Cen...

By

Microsoft

GoDaddy SSL Certificates

By

GoDaddy.com

Microsoft IIS

By

Microsoft
See more technologies

Shanghai Junshi Biosciences News & Media

Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors

VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint

--the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcinoma

--5th approved indication by NMPA significantly expands eligible patient population --5th approved indication by NMPA significantly expands eligible patient population
Subscribe to "Shanghai Junshi Biosciences" News

Frequently Asked Questions regarding Shanghai Junshi Biosciences

Where are Shanghai Junshi Biosciences’s headquarters?

Shanghai Junshi Biosciences’s headquarters are in No 781, Cailun Rd, Zhangjiang, Shanghai, Shanghai, China

What is Shanghai Junshi Biosciences’s phone number?

Shanghai Junshi Biosciences’s phone number is +86 21 5079 6193

What is Shanghai Junshi Biosciences’s stock symbol?

Shanghai Junshi Biosciences’s stock symbol is 1877

What is Shanghai Junshi Biosciences’s official website?

Shanghai Junshi Biosciences’s official website is junshipharma.com

What is Shanghai Junshi Biosciences’s Revenue?

Shanghai Junshi Biosciences’s revenue is $400 Million

What is Shanghai Junshi Biosciences’s SIC code?

Shanghai Junshi Biosciences’s SIC: 28,283

What is Shanghai Junshi Biosciences’s NAICS code?

Shanghai Junshi Biosciences’s NAICS: 32541,325

How many employees are working in Shanghai Junshi Biosciences?

Shanghai Junshi Biosciences has 616 employees

What is Shanghai Junshi Biosciences’s industry?

Shanghai Junshi Biosciences is in the industry of: Manufacturing, Pharmaceuticals

What is Shanghai Junshi Biosciences's tech stack?

The technologies that are used by Shanghai Junshi Biosciences are: Jira, Microsoft Dynamics 365 Business Central, GoDaddy SSL Certificates, Microsoft IIS

Who is Shanghai Junshi Biosciences's CEO?

Shanghai Junshi Biosciences's CEO is Ning Li

See more information about Shanghai Junshi Biosciences
4.4/5 on G2 Crowd